Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
तुलना करने के लिए मीट्रिक्स | NKTR | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधNKTRपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −3.1x | 0.0x | −0.5x | |
PEG अनुपात | −0.10 | 0.00 | 0.00 | |
क़ीमत/बुक | 29.6x | 0.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 4.7x | 2.1x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 326.1% | 52.0% | 49.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | 23.6% | 7.4% | अनलॉक करें |